In the phase 2 EVITA trial, vitamin C did not slow clonal growth but was linked to fewer serious adverse events and longer exploratory survival.
News|Articles|November 14, 2025
5 Takeaways From JADPRO Live 2025
Author(s)Bridget Hoyt
Fact checked by: Gina Mauro, Tracy Ann Politowicz
Here are 5 presentations that oncology APPs should know about, from patient management to practice management.
Advertisement
Advertisement
JADPRO Live 2025 provides a platform for leaders in oncology advanced practice to share research and best practices with their peers. From case studies in managing difficult adverse effects to optimizing advanced practice provider (APP) teams for better patient care, the event featured experts in care across the continuum of oncology.
Related to this article
Marieta Branis, APN, discusses individualized breast cancer care, monitoring for ADC and oral therapy toxicities, younger patients, and survivorship.
Real-time check-ins from patients with MBC showed quality of life dipped when depression, anxiety, or fatigue rose above usual levels.
FDA approves tucatinib maintenance with trastuzumab and pertuzumab for HER2+ breast cancer based on HER2CLIMB-05.
Beth Faiman details the new IMS/IMWG consensus definition of cure for multiple myeloma, requiring 5 years of treatment-free remission.
Following WCLC 2026, Katherine Kuhns details how perioperative immunotherapy, AI patient tools, and wearables are transforming thoracic surgical nursing care.
Beth Faiman details the new IMS/IMWG consensus definition of cure for multiple myeloma, requiring 5 years of treatment-free remission.
Five-week hypofractionated radiation after prostatectomy showed similar 5-year cancer control and quality of life but more grade 3 urinary toxicity.
Advertisement
Advertisement